Tompkins Financial’s Sarepta Therapeutics SRPT Stock Holding History

Tompkins Financial’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-162	Closed	-$19.7K	–	584
2024 Q4	$19.7K	Hold	162	–	–	﹤0.01%	394
2024 Q3	$20.2K	Hold	162	–	–	﹤0.01%	419
2024 Q2	$25.6K	Hold	162	–	–	﹤0.01%	406
2024 Q1	$21K	Hold	162	–	–	﹤0.01%	426
2023 Q4	$15.6K	Hold	162	–	–	﹤0.01%	451
2023 Q3	$19.6K	Hold	162	–	–	﹤0.01%	406
2023 Q2	$18.6K	Hold	162	–	–	﹤0.01%	414
2023 Q1	$22.3K	Hold	162	–	–	﹤0.01%	409
2022 Q4	$21K	Hold	162	–	–	﹤0.01%	411
2022 Q3	$18K	Hold	162	–	–	﹤0.01%	422
2022 Q2	$12K	Hold	162	–	–	﹤0.01%	458
2022 Q1	$13K	Hold	162	–	–	﹤0.01%	474
2021 Q4	$15K	Hold	162	–	–	﹤0.01%	277
2021 Q3	$15K	Buy	+162	New	+$12.5K	﹤0.01%	305
2021 Q1	$12K	Hold	162	–	–	﹤0.01%	352
2020 Q4	$28K	Hold	162	–	–	0.01%	295
2020 Q3	$23K	Hold	162	–	–	﹤0.01%	290
2020 Q2	$26K	Hold	162	–	–	0.01%	277
2020 Q1	$16K	Buy	+162	New	+$18.5K	﹤0.01%	293

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Tompkins Financial's SRPT Position: Q1 2025 in Review

Tompkins Financial sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 162 shares — an estimated $19.7K sold.

Tompkins Financial first reported a position in SRPT in Q1 2020 and held it in 19 quarters. The position peaked at $28K in Q4 2020. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Tompkins Financial reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Tompkins Financial sold 162 Sarepta Therapeutics shares in Q1 2025, an estimated $19.7K.
Tompkins Financial first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 19 quarters.
Tompkins Financial's Sarepta Therapeutics position peaked at $28K in Q4 2020.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Tompkins Financial's 13F filing for Q1 2025, filed 7 Apr 2025.